Background {#s1}
==========

It is estimated that each year more than 9 million new cases of tuberculosis are registered, and it kills three million people per year \[[@R01]\]. The WHO report shows that 3.7% patients worldwide are multi-drug resistant \[[@R02]\]. It is of interest to design new compounds due to total drug resistance (TDR) and multi drug resistance (MDR) \[[@R03],[@R04], [@R05],[@R06]\]. Major energy dependent proteases are found in bacteria \[[@R07],[@R08]\]. Cutin like proteases (Clp) of Mycobacterium tuberculosis plays key role in the assembly of the mycobacterial cell wall and is essential for its growth \[[@R09]\]. Clps also plays a critical role in response to stress conditions \[[@R10]\]. The complex of Clp protease constitutes a group of dual heptameric rings structures in proteolytic subunit surrounded by a hexameric ring in ATPase subunit \[[@R11]\]. It is known that although ClpP1 and ClpP2 form tetradecamers by themselves, they are however inactive. The uncommon characteristics of this complex with both the subunits i.e. ClpP1P2 protease, makes it an atypical target for drug development \[[@R12]\]. The proteolysis mediated death of gram-positive bacteria (Streptococcus, Bacillus subtilis, and Enterococcus) by acyldepsipeptides (ADEPs) targeting Clps is known \[[@R13]\]\[[@R14]\].

In vivo and in vitro investigation have shown that synergistic binding of ADEP and ClpP promotes uncontrolled proteolytic activity directing excessive filamentation and ultimately leading to cell necrosis \[[@R15]\]. Therefore, it is of interest to document the structural basis of ADEPs targeting Clp2 of mycobacterium tuberculosis using modeling and binding data.

Methodology {#s2}
===========

Selection of compounds: {#s2a}
-----------------------

The established acyldepsipeptide compounds and its derivatives in addition to those belonging to the enopeptin class of natural product were selected from literature \[[@R16],[@R17]\]. ADEP2, ADEP3, ADEP4, IDR-10001 and IDR-10011 were selected for the binding interactions against Clp2 in the present study ([Figure 1](#F1){ref-type="fig"}).

Preparation of protein: {#s2b}
-----------------------

The structure of Clp2 was retrieved from Protein Data Bank (PDB) with PDB ID 4U0G \[[@R18]\] ([Figure 2](#F2){ref-type="fig"}). The structure was further made bonafide by preparing the protein by PrepWiz module of Schrodinger suite. The protein was first pre-processed by creating zero order bonds to metals and adding disulphide bonds and assigning the bond orders and hydrogens. Missing loops and side chains were filled using Prime Module of Schrodinger. After pre-processing, H bonds were assigned to the structure followed by OPLS 2005 force field energy minimization \[[@R19]\]. Final structure thus obtained was saved in .pdb format for further studies.

Structure Similarity search: {#s2c}
----------------------------

Similarity search was performed by Binary Finger Print Based Tanimoto similarity equation considering all the ADEPs as query molecules to retrieve compounds with similarity threshold of 95 % against NCBI's Pubchem compound database \[[@R21]\].

Molecular docking of compounds: {#s2d}
-------------------------------

All the ligands were docked at the active site of Clp2 employing MolDock scoring function embedded in Molegro Virtual Docker (MVD) \[[@R22],[@R23], [@R24]\]. Docking parameters were set to maximum iteration of 1500, 0.20Å as grid resolution and maximum population size of 50. Simplex evolution was set at maximum steps of 300 with neighbourhood distance factor of 1. Binding affinity with protein was evaluated on the basis of the internal hydrogen bonds interactions, sp2-sp2 torsions and internal ES (Internal electrostatic Interaction). Post docked energy of the ligand-receptor complex was minimized by Nelder Mead Simplex Minimization (using non-grid force field and H bond directionality) \[[@R25]\]. On the basis of re-rank score (affinity score) high affinity compound was selected from each dataset.

Preparation of compounds: {#s2e}
-------------------------

The ligands were optimized using LigPrep module of Schrödinger suite, 2013 (Schrodinger. LLC, New York, NY) employing OPLS 2005 force field algorithm \[20\]. The ionizations of the ligand were retained at the original state and were desalted and saved in .sdf format.

Bioactivity and ADMET profiling of compounds: {#s2f}
---------------------------------------------

The complete ADMET properties were calculated using admetSAR \[[@R26]\]. Biological activity of the ligands was predicted using Molinspiration webserver (© Molinspiration Cheminformatics 2014).

Pharmacophore Mapping: {#s2g}
----------------------

Pharmacophoric mapping which involves hydrogen bond interaction, ligand interaction patterns and hydrophobic interactions were evaluated using Accelrys Discovery Studio 3.5 DS Visualizer \[[@R27]\].

Results and Discussion: {#s3}
=======================

[Table 1](#T1){ref-type="table"} shows the re-rank (affinity) scores for Clp2 inhibitors similar to minimum inhibitory concentration (MIC) reported by Ollinger et al. (2012) \[[@R16]\]. Docking (re-rank) score for ADEP2 is with highest binding affinity ([Table 1](#T1){ref-type="table"}). [Figure 2](#F2){ref-type="fig"} shows ADEP2 bound at the active site of Clp2 (PDB: 4U0G). Structural analysis of ADEP2 shows that 3, 5 difluoro phenyl group connects the core structure with R configuration (a distinguishing feature from ADEP3 which has S configuration) having superior activity (MIC=50) and maximum affinity (Re-rank Score = -142.495). It is noted that the binding affinity results shows ADEP2 as a high affinity binder to Clp2 as described elsewhere by Ollinger et al. (2012) \[[@R16]\]. It shows ADEP2 to have best activity (MIC) to bring about ADEP2 mediated growth inhibition ([Table 1](#T1){ref-type="table"}). In addition, studies by Brötz-Oesterhelt et al. (2005) \[[@R17]\] also reported that ADEP2 to have an anti-bacterial activity against gram-positive bacteria in in vitro and in rodent models of bacterial infection. The binding affinity prediction that ADEP2 to be an appreciable antimicrobial agent targeting Clp2 corroborates with the data of Ollinger et al. (2012) and Brötz-Oesterhelt et al. (2005) \[[@R16],[@R17]\].

Virtual screening for structures was performed against Pubchem database (taking compound ADEP2 as query) to search for better molecules with superior pharmacological profile than compound ADEP2. A total of 33 compounds structurally similar to compound ADEP2 were retrieved. All the similar compounds retrieved hitherto were docked against the Clp2 structure. Compound SCHEMBL14131185 with Pubchem Id: 59753367 ([Figure 3](#F3){ref-type="fig"}) showed highest binding affinity amongst similar 33 compounds retrieved. It should be noted that SCHEMBL14131185 showed higher affinity to Clp2 than its parent compound ADEP2. It shows less activity for enzyme inhibition ([Table 2](#T2){ref-type="table"}) despite high predicted activity scores. The ADMET profiles are poor when compared to its parent compound ADEP2 ([Table 3](#T3){ref-type="table"}). In addition, compound SCHEMBL14131185 was predicted to be Ames toxic despite high good affinity.

The appreciable binding is due to H-bonding and electrostatic interactions for ADEP2. The descriptors energy values of external ligand interactions contribute 10.5 folds higher stability than internal ligand interactions for ADEP2. External ligand interactions were stabilized mostly by Piece wise linear potentials guided stearic energy, while the torsional strain contributes for the stability in internal ligand interactions. [Table 4](#T4){ref-type="table"} shows affinity energy profile of ADEP2 and its similar SCHEMBL14131185 (Pubchem Id: 59753367).

ADEP2 shows van der Waals interactions with Pro79, Gln47, Gly80, Ile157, Leu139, Ala111. Pro137, Val114, Leu86, Met160 and Thr84 and electrostatic interactions with Ser140, Phe83, Ser138, Gly81, Gly82 and Met164. ADEP2 is a hydrogen bond donor to Ser 140 ([Figure 4](#F4){ref-type="fig"}). The electrostatic interactions and hydrophobic interactions of ADEP2 in the binding cavity of Clp2 is show in ([Figure 5](#F5){ref-type="fig"}). These data along with the observation made by Brötz- Oesterhelt, et al. (2005) \[[@R17]\] suggests ADEp2 as a potential candidate for Clp2 inhibition.

Conclusion: {#s4}
===========

The inhibition of Mtb Clp2 by ADEP2 is known. However, its molecular basis is unknown. Therefore, it is of interest to document its binding affinity, enzyme activity and ADME profiles. The predicted activity and ADMET properties were estimated. This data suggest ADEP2 having improved binding features with Mtb Clp 2 having acceptable ADMET properties. This is in agreement with known in vitro data for ADEP2 inhibition with Mtb Clp 2 protease.
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###### The activity of the compounds and the predicted binding affinity (re-rank score) is listed.

  Compound                                                                                 Activity on M.tuberculosis+   Binding affinity (Re-rank Score)
  ---------------------------------------------------------------------------------------- ----------------------------- ----------------------------------
  ADEP2                                                                                    25                            -142.495
  ADEP3                                                                                    100                           -97.998
  ADEP4                                                                                    50                            -100.089
  IDR-10001                                                                                100                           -117.216
  IDR-10011                                                                                50                            -112.300
                                                                                                                         
  +MIC99 (μg/ml) was determined against Clp2 of Mycobacterium tuberculi on solid medium.                                 

###### Bioactivity prediction of Parent and similar compounds against various drug targets

  Compound                                                                                                                                                                                                                 GPCR ligand   Ion channel modulator   Kinase inhibitor   Nuclear receptor ligand   Protease inhibitor   Enzyme inhibitor
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------- ----------------------- ------------------ ------------------------- -------------------- ------------------
  ADEP2                                                                                                                                                                                                                    0.15          -0.12                   -0.36              -0.11                     -0.17                1.38\*
  ADEP3                                                                                                                                                                                                                    -0.07         -0.3                    -0.2               -0.3                      -0.08                -0.18
  ADEP4                                                                                                                                                                                                                    -0.11         0.06                    -0.24              -0.18                     -0.05                -0.03
  IDR-10001                                                                                                                                                                                                                -0.11         -0.51                   -0.35              -0.43                     -0.13                -0.08
  IDR-10011                                                                                                                                                                                                                -0.17         -0.41                   -0.21              -0.22                     -0.02                -0.03
  SCHEMBL14131185                                                                                                                                                                                                          -0.28         -0.72                   -0.42              0.22                      -0.13                -0.16
                                                                                                                                                                                                                                                                                                                                   
  \*ADEP 2 showing activity highest enzyme inhibition and least activity against other drug targets testifying its target specificity against enzymes (in the present case Clp2); SCHEMBL14131185 (Pubchem Id: 59753367)                                                                                                           

###### ADMET profiles of parent compound and its respective similar

                                                                                                                                                                              ADEP2             SCHEMBL14131185 Pubchem Id: 59753367                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- -------------------------------------- ----------------- --------
  Absorption                                                                                                                                                                                                                                             
  Blood-Brain Barrier                                                                                                                                                         BBB+              0.746                                  BBB+              0.842
  Human Intestinal Absorption                                                                                                                                                 HIA+              0.993                                  HIA+              0.834
  Caco-2 Permeability                                                                                                                                                         Caco2-            0.561                                  Caco2-            0.537
  P-glycoprotein Substrate                                                                                                                                                    Substrate         0.837                                  Substrate         0.809
  P-glycoprotein Inhibitor                                                                                                                                                    Inhibitor         0.891                                  nhibitor          0.782
  Distribution and Metabolism                                                                                                                                                                                                                            
  CYP450 2C9 Substrate                                                                                                                                                        Non-substrate     0.807                                  Non-substrate     0.836
  CYP450 3A4 Substrate                                                                                                                                                        Substrate         0.798                                  Substrate         0.657
  CYP450 1A2 Inhibitor                                                                                                                                                        Non-inhibitor     0.654                                  Non-inhibitor     0.771
  CYP450 2D6 Inhibitor                                                                                                                                                        Non-inhibitor     0.81                                   Non-inhibitor     0.578
  CYP450 3A4 Inhibitor                                                                                                                                                        Inhibitor         0.667                                  Inhibitor         0.705
  Excretion and Toxicity                                                                                                                                                                                                                                 
  Human Ether-a-go-go-Related Gene Inhibition                                                                                                                                 Inhibitor         0.6113                                 Inhibitor         0.8209
  AMES Toxicity                                                                                                                                                               Non-AMES toxic    0.532                                  AMES TOXIC        0.7
  Carcinogens                                                                                                                                                                 Non-carcinogens   0.686                                  Non-carcinogens   0.945
  Honey Bee Toxicity                                                                                                                                                          Low HBT           0.664                                  Low HBT           0.837
  Acute Oral Toxicity                                                                                                                                                         III               0.596                                  II                0.708
                                                                                                                                                                                                                                                         
  \*Compound SCHEMBL14131185 similar to ADEP2 demonstrating AMES toxicity, with high probability value therefore can be excluded from further pharmacological investigation                                                                              

###### Binding energy profile of ADEP2 and its respective similar of Clp2

  Energy Descriptors                       ADEP2      SCHEMBL14131185
  ---------------------------------------- ---------- -----------------
  Total Energy (Rerank Score)              -142.495   -162.543
  External Ligand interactions             -155.974   -185.367
  Protein - Ligand interactions            -155.974   -185.367
  Steric (by PLP)                          -124.074   -147.787
  Steric (by LJ12-6)                       -27.691    -34.671
  Hydrogen bonds                           -4.209     -2.91
  Electrostatic (short range)              -2.035     0
  Electrostatic (long range)               -0.81      0
  Internal Ligand interactions             13.479     22.825
  Torsional strain                         7.44       1.88
  Torsional strain (sp2-sp2)               0          0
  Hydrogen bonds                           0          0
  Steric (by PLP)                          -3.882     4.076
  Steric (by LJ12-6)                       9.862      16.868
  Electrostatic                            7.673      0
                                                      
  SCHEMBL14131185 (Pubchem Id: 59753367)              

![Structures for ADEP compounds and their derivatives.](97320630012092F1){#F1}

![ADEP 2 bound at the active site of Clp 2.](97320630012092F2){#F2}

![Structure of SCHEMBL14131185 Pubchem Id: 59753367 a similar compound to ADEP2](97320630012092F3){#F3}

![Ligand-receptor interactions of compound ADEP2 in the active site of Clp2 (PDB 4U0G). Residues in green contribute in van der Waals interaction while residues in pink participate in electrostatic interactions. Ser 140 form hydrogen bond acceptor from the ligand (green arrow)](97320630012092F4){#F4}

![(A) Electrostatic Interaction of ADEP2 in Clp2. Electronegative and electropositive surface of the cavity is shown as red and blue colors respectively. White surface is electrically neutral. (B) Hydrophobic interactions of ADEP2 in the active site of receptor. Cavity is shown with hydrophobic intensities. The hydrophobic intensity of the binding site ranges from -3.00 (least hydrophobic area - blue shade) to 3.00 (highly hydrophobic area - brown shade).](97320630012092F5){#F5}
